Vaxil Bio Ltd.
VXL.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 83.33% | 28.71% | -63.92% | -73.43% | -53.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.19% | -23.95% | -71.15% | -80.85% | -68.40% |
| Operating Income | -9.19% | 23.95% | 71.15% | 80.85% | 68.40% |
| Income Before Tax | 2.23% | 30.90% | 71.49% | 80.85% | 68.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.23% | 30.90% | 71.49% | 80.85% | 68.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.23% | 30.90% | 71.49% | 80.85% | 68.40% |
| EBIT | -9.19% | 23.95% | 71.15% | 80.85% | 68.40% |
| EBITDA | -- | -- | 106.87% | 99.76% | 78.38% |
| EPS Basic | 2.17% | 30.81% | 71.46% | 80.86% | 68.41% |
| Normalized Basic EPS | 2.20% | 30.86% | 72.87% | 80.85% | 68.39% |
| EPS Diluted | 2.17% | 30.81% | 71.46% | 80.86% | 68.41% |
| Normalized Diluted EPS | 2.20% | 30.86% | 72.87% | 80.85% | 68.39% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |